ArticleFrontiers in oncology2025
Survival prognosis evaluation in advanced breast cancer patients: a study on the application of the advanced lung cancer inflammation index.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prognostic Value of the Advanced Lung Cancer Inflammation Index for Predicting in-Hospital Mortality in Intensive Care Unit Patients with Septic Shock: A Retrospective Cohort Study.Journal of inflammation research · 2026Article
- Machine learning and SHAP value interpretation for predicting the response to neoadjuvant chemotherapy and long-term clinical outcomes in Chinese female breast cancer.Annals of medicine · 2025Article
- Advanced lung cancer inflammation index as a diagnostic indicator of bone turnover in osteoporotic fracture patients: a non-linear analysis.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation and nutritional status play critical roles in tumor initiation and progression. Advanced Lung Cancer Inflammation Index (ALI) has gained widespread attention as a novel biomarker for cancer prognosis evaluation. Methods: This retrospective study analyzed 163 advanced breast cancer patients with distant metastasis (Guangxi Medical University Cancer Hospital, 2016-2023). Patients were stratified into high-ALI (n=64) and low-ALI (n=99) groups via K-means clustering. Kaplan-Meier survival curves with log-rank testing were used to assess survival differences, while Cox proportional hazards models were employed to evaluate the independent prognostic value of ALI. The predictive performance of ALI was assessed using time-dependent ROC curves. Results: High ALI correlated with superior overall survival (log-rank p=0.0024) [HR=2.493 (95%CI 1.350-4.606) p = 0.004]. Multivariate analysis confirmed ALI as an independent prognostic factor (HR=0.39, 95% CI 0.16-0.95, p=0.037). ALI demonstrated stable predictive accuracy with 3-year AUC=0.645 and 5-year AUC=0.650 (C-index=0.65). Subgroup analyses confirmed prognostic consistency across clinical characteristics (p-interaction>0.05). Conclusion: ALI is an independent prognostic factor for advanced breast cancer patients with good predictive ability. It provides an important supplementary prognostic marker for clinical practice and can help optimize personalized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.